multiple sclerosis

5 Biggest New Drugs Approved in 2019 So Far
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Flag link:
Tackling the remaining challenges of multiple sclerosis
Tackling the remaining challenges of multiple sclerosis
Pharmaforum
Merck KGaA
MS
multiple sclerosis
evobrutinib
Flag link:
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
Flag link:
Upcoming events – Atara and Aslan await validating results
Upcoming events – Atara and Aslan await validating results
EP Vantage
Atara
Tab-cel
ATA188
multiple sclerosis
Aslan
varlitinib
Flag link:
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
Endpoints
Biogen
Alkermes
MS
multiple sclerosis
Vumerity
clinical trials
Flag link:
Novartis multiple sclerosis product Gilenya approved in China
Novartis multiple sclerosis product Gilenya approved in China
Pharmaceutical Business Review
China
Novartis
multiple sclerosis
Gilenya
Flag link:
MediciNova gets bounce after revealing clinical plan for MS therapy
MediciNova gets bounce after revealing clinical plan for MS therapy
BioCentury
MedicNova
clinical trials
ibudilast
multiple sclerosis
Flag link:
Atara Reports Initial Data for Multiple Sclerosis Candidate
Atara Reports Initial Data for Multiple Sclerosis Candidate
Yahoo/Zacks.com
Atara
ATA188
clinical trials
multiple sclerosis
Flag link:
Novartis wins Gilenya reprieve as judge blocks generics, for now
Novartis wins Gilenya reprieve as judge blocks generics, for now
Yahoo/Reuters
Novartis
generics
Gilenya
multiple sclerosis
Flag link:
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Flag link:
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Flag link:
Upcoming events – key tests approach for Biogen and Kalvista
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Flag link:
Upcoming events – Phase III data for Chiasma and Novartis
Upcoming events – Phase III data for Chiasma and Novartis
EP Vantage
Chiasma
acromegaly
Mycapssa
clinical trials
multiple sclerosis
Novartis
ofatumumab
Flag link:
Sanofi Joins Drugmakers' Bid to Treat Patients With Software
Sanofi Joins Drugmakers' Bid to Treat Patients With Software
Yahoo/Bloomberg
Sanofi
digital pharma
Happify Health
digital therapeutics
depression
multiple sclerosis
Flag link:
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Endpoints
Novartis
Mayzent
siponimod
multiple sclerosis
Flag link:
FDA Raises Concerns With Novartis in Clinical Inspection
FDA Raises Concerns With Novartis in Clinical Inspection
RAPS.org
Novartis
FDA
Mayzent
siponimod
clinical trials
multiple sclerosis
Flag link:
German Merck finally gets yes for MS drug Mavenclad
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Flag link:
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Endpoints
FDA
Merck KGaA
cladribine
MA
multiple sclerosis
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:

Pages